Good morning :)
$
₹
V

Valneva SE ADR

VALN

NASDAQ
V

Valneva SE ADR

VALN

NASDAQ
$5.744.33% (+0.23)
$
₹
$5.744.33% (+0.23)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Small Cap

With a market cap of $504.5M the stock is ranked 3255

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

5.74
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.1
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

—
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

-110.29%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 4 analysts reports

Buy
3 analysts
Hold
0 analyst
Sell
1 analyst

Price Upside

+122.78%

Earnings Growth

+24.23%

Rev. Growth

-13.65%

See Detailed Forecast

Company Profile

Company Profile

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.
Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and IXCHIQ/ VLA1553, a single-dose, live-attenuated vaccine for the prevention of disease caused by chikungunya virus. The company also develops VLA15, a vaccine candidate against Borrelia, the bacterium that causes Lyme disease; S4V2, a tetravalent bioconjugate vaccine candidate against shigellosis, a diarrheal infection caused by Shigella bacteria; VLA1601, a vaccine candidate targeting the Zika virus, a mosquito-borne viral disease; VLA1554, a vaccine candidate targeting human metapneumovirus; VLA84, a vaccine candidate targeting the prevention of primary symptomatic clostridium difficile infection; PF-07307405, a vaccine candidate to prevent Lyme disease cases in individuals aged five years and older and VLA2112, a vaccine candidate to treat patients with epstein-barr virus. It sells its products in the United States, Canada, Germany, Austria, Nordics, the United Kingdom, France, rest of Europe, and internationally. Valneva SE was founded in 1998 and is based in Saint-Herblain, France.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.67
50.67
1Y Return
36.27%
36.27%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
28.90
28.90
1Y Return
58.2%
58.2%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
37.21%
37.21%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
32.21
32.21
1Y Return
24.59%
24.59%
Buy Reco %
81.25
81.25
Regeneron Pharmaceuticals Inc
REGN
Regeneron Pharmaceuticals Inc
P/E Ratio
21.24
21.24
1Y Return
51.74%
51.74%
Buy Reco %
67.85
67.85
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Higher price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 122.78% growth, versus a trailing 3-year CAGR of -23.87%.

2026
Current$5.51Baseline
Analyst Target - 1 year
Target$12.28+122.78%

All values in $

202220232024202520262027$6.45$8.96$11.48Target+122.78%
2026
Current$5.51Baseline
Analyst Target - 1 year
Target$12.28+122.78%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies -13.65% growth, versus a trailing 3-year CAGR of -21.52%.

2025
Current$174.65Baseline
Forecast for Dec 2026
High$170.15-2.58%
Average$150.81-13.65%
Low$144.28-17.39%

All values in $ Million

202120222023202420252026348.08361.30153.71169.57174.65Low-17.39%Average-13.65%High-2.58%
2025
Current$174.65Baseline
Forecast for Dec 2026
High$170.15-2.58%
Average$150.81-13.65%
Low$144.28-17.39%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.49Baseline
Forecast for Dec 2026
High$-1.13+24.23%
Average$-1.13+24.23%
Low$-1.13+24.23%

All values in $

202120222023202420252026-3.18-2.56-1.37-0.18-1.49Low+24.23%Average+24.23%High+24.23%
2025
Current$-1.49Baseline
Forecast for Dec 2026
High$-1.13+24.23%
Average$-1.13+24.23%
Low$-1.13+24.23%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

29.4
-44.3
47.6
-50
30.9
-32
35.5
-31.7
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue32.7538.0645.8252.9449.2348.3329.4047.6830.9035.51
Net Income58.90-24.93-9.23-36.98-9.23-11.58-44.35-50.01-32.07-31.71
Net Profit Margin179.85%-65.50%-20.15%-69.86%-18.75%-23.97%-150.82%-104.89%-103.78%-89.31%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Valneva SE ADR -5.74-
AbbVie Inc50.6750.450.60
Amgen Inc28.9021.552.77
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare VALN with any stock or ETF
Compare VALN with any stock or ETF
Comparing from
VALN
ABBV
AMGN
Loading...

Frequently asked questions

  1. Valneva SE ADR (VALN) share price today is $5.74 as of November 5, 2026 at 12:25 AM IST. The stock touched a day high of $5.77 and a day low of $5.59.

  2. Valneva SE ADR stock trades on NASDAQ under the ticker symbol VALN.

  3. Valneva SE ADR's market capitalization is $504.46M as of November 5, 2026 at 12:25 AM IST.

  4. Valneva SE ADR's price-to-earnings (P/E) ratio is N/A as of November 4, 2026.

  5. Valneva SE ADR's price-to-book (P/B) ratio is 5.74 as of November 4, 2026.

  6. Yes, You can buy Valneva SE ADR shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Valneva SE ADR shares in three steps: 1. Search Valneva SE ADR on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Valneva SE ADR trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Valneva SE ADR (VALN) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 1.7394 shares at the current price of $5.74.

Loading...